# Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

> **NCT07671911** · PHASE3 · RECRUITING · sponsor: **Trevi Therapeutics** · enrollment: 306 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** NAL ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07671911
- **Lead sponsor:** Trevi Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2028-06
- **Final completion:** 2028-07
- **Target enrollment:** 306 (ESTIMATED)
- **Last updated:** 2026-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671911, "Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*